Cite
Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.
MLA
Ayuk, Francis, et al. “Clinical Impact of Human Jurkat T-Cell-Line-Derived Antithymocyte Globulin in Multiple Myeloma Patients Undergoing Allogeneic Stem Cell Transplantation.” Haematologica, vol. 93, no. 9, Sept. 2008, pp. 1343–50. EBSCOhost, https://doi.org/10.3324/haematol.12665.
APA
Ayuk, F., Perez-Simon, J. A., Shimoni, A., Sureda, A., Zabelina, T., Schwerdtfeger, R., Martino, R., Sayer, H. G., Alegre, A., Lahuerta, J.-J., Atanackovic, D., Wolschke, C., Nagler, A., Zander, A. R., San Miguel, J. F., & Kröger, N. (2008). Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. Haematologica, 93(9), 1343–1350. https://doi.org/10.3324/haematol.12665
Chicago
Ayuk, Francis, José A Perez-Simon, Avichai Shimoni, Anna Sureda, Tatjana Zabelina, Rainer Schwerdtfeger, Rodrigo Martino, et al. 2008. “Clinical Impact of Human Jurkat T-Cell-Line-Derived Antithymocyte Globulin in Multiple Myeloma Patients Undergoing Allogeneic Stem Cell Transplantation.” Haematologica 93 (9): 1343–50. doi:10.3324/haematol.12665.